Free tool
FAERS Monitor: Duvyzat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217865 or its brand name (Duvyzat, Givinostat Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
635
Serious
172
27% of reports
Hospitalization
70
Death reported
17
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- platelet count decreased132
- diarrhoea85
- blood triglycerides increased60
- abdominal discomfort46
- vomiting45
- nausea44
- weight increased40
- thrombocytopenia39
- product dose omission issue38
- off label use27
- pyrexia27
- abdominal pain upper25
- fatigue21
- abdominal pain20
- fall20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2024 | 49 |
| 2025 | 374 |
| 2026 | 210 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,524 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood triglycerides increasedSignal | 60 | 112.9 | 88.7 | 6,525 |
| platelet count decreasedSignal | 132 | 41.1 | 35.3 | 5,140 |
| thrombocytopeniaSignal | 39 | 11.6 | 8.5 | 367 |
| abdominal discomfortSignal | 46 | 9.1 | 6.9 | 325 |
| weight increasedSignal | 40 | 5.9 | 4.4 | 160 |
| diarrhoeaSignal | 85 | 4.4 | 3.6 | 224 |
| product dose omission issueSignal | 38 | 4.3 | 3.1 | 94 |
| abdominal pain upperSignal | 25 | 4.0 | 2.7 | 54 |
| vomitingSignal | 45 | 3.2 | 2.4 | 66 |
| abdominal painSignal | 20 | 2.8 | 1.9 | 22 |
| pyrexiaSignal | 27 | 2.6 | 1.8 | 25 |
| fall | 20 | 2.0 | 1.3 | 9 |
| nausea | 44 | 1.8 | 1.4 | 17 |
| off label use | 27 | 1.0 | 0.7 | 0 |
| fatigue | 21 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.